Havishakrishna Sarma, DO
Internal Medicine · Portage, INNPI 1992934020
Payments from drug & device makers
Across 224 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$806
- Vanda Pharmaceuticals Inc.$385
- Otsuka America Pharmaceutical, Inc.$263
- Bayer$221
- Lilly USA, LLC$208
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,94598%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,184 |
| Novo Nordisk | 32 | $806 |
| Vanda Pharmaceuticals Inc. | 11 | $385 |
| Otsuka America Pharmaceutical, Inc. | 12 | $263 |
| Bayer | 7 | $221 |
| Lilly USA, LLC | 7 | $208 |
| Novartis | 8 | $201 |
| Johnson & Johnson(2 entities) | 2 | $151 |
| GSK | 10 | $146 |
| AstraZeneca | 8 | $139 |
| Amgen(2 entities) | 2 | $138 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Vifor Pharma, Inc. | 1 | $125 |
| Pfizer | 6 | $124 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $119 |
| Lundbeck LLC | 4 | $85 |
| Watermark Medical, Inc. | 1 | $71 |
| Eisai Inc. | 3 | $66 |
| Hikma Pharmaceuticals USA | 3 | $60 |
| Orexo US, Inc. | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Gilead | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Philips North America LLC | 1 | $22 |
| Indivior Inc. | 1 | $20 |
| Merck | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Biomerieux Inc | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$131
- Veltassa$125
- Ozempic$125
- KRYSTEXXA$125
- SOLIQUA 100/33$125
- JARDIANCE$125
- RYBELSUS$122
- Kerendia$114
- Tresiba$110
How this compares
$5,072 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 140 | $122,221 |
| Enbrel SureclickEtanercept | 13 | $113,052 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 141 | $102,400 |
| EliquisApixaban | 318 | $102,186 |
| OzempicSemaglutide | 77 | $77,775 |
| MounjaroTirzepatide | 47 | $46,202 |
| LinzessLinaclotide | 42 | $43,888 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $42,895 |
| XifaxanRifaximin | 31 | $40,713 |
| RybelsusSemaglutide | 25 | $37,345 |
| XareltoRivaroxaban | 113 | $36,071 |
| RexultiBrexpiprazole | 22 | $33,374 |
| TrulicityDulaglutide | 22 | $29,879 |
| FarxigaDapagliflozin Propanediol | 54 | $26,658 |
| Nurtec OdtRimegepant Sulfate | 20 | $26,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $146 | $150,937231 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $24 | $138,372178 claims |
| PfizerEliquis, Nurtec Odt | $124 | $128,836338 claims |
| Novo NordiskOzempic, Rybelsus | $806 | $115,120102 claims |
| Lilly USA, LLCMounjaro, Trulicity | $208 | $76,08169 claims |
| AbbVieLinzess, Fetzima | $1,184 | $48,53160 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $119 | $40,71331 claims |
| Johnson & JohnsonXarelto | $151 | $36,071113 claims |
| AstraZenecaFarxiga, Brilinta | $139 | $34,00565 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $263 | $33,37422 claims |
| NovartisEntresto | $201 | $20,94853 claims |
| MerckBelsomra, Verquvo | $20 | $16,56842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Portage
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.